Takeda hustles to prevent cancer drug shortage after FDA warning letter

Takeda took a slap from the FDA in June when inspectors slammed its Hikari, Japan, plant in a warning letter. It turns out that fixing those problems helped trigger a local shortage of the chemotherapy drug leuprorelin—and now, the drugmaker is scrambling to shore up supply to keep the shortage from spreading.